Vision-Sciences grosses $10m from private equity sale:
This article was originally published in Clinica
Vision-Sciences, of Natick, Massachusetts, has raised $10m in a sale of common stock to two company insiders and two independent financial investors. The funds will be used in product development and to extend activities to new markets. Vision-Sciences develops,manufactures and markets flexible endoscopic products utilising sterile, disposable sheaths.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.